NO164654C - Analogifremgangsmaate for fremstilling av terapeutisk aktive (2-okso-1,2,3,5-tetrahydroimidazo (2,1-b)kinazolinyl)-oksylakylamider. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive (2-okso-1,2,3,5-tetrahydroimidazo (2,1-b)kinazolinyl)-oksylakylamider.

Info

Publication number
NO164654C
NO164654C NO850564A NO850564A NO164654C NO 164654 C NO164654 C NO 164654C NO 850564 A NO850564 A NO 850564A NO 850564 A NO850564 A NO 850564A NO 164654 C NO164654 C NO 164654C
Authority
NO
Norway
Prior art keywords
oxylacylamides
chinazolinyl
tetrahydroimidazo
oxo
preparation
Prior art date
Application number
NO850564A
Other languages
English (en)
Norwegian (no)
Other versions
NO164654B (no
NO850564L (no
Inventor
John H Fried
Michael C Venuti
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO850564L publication Critical patent/NO850564L/no
Publication of NO164654B publication Critical patent/NO164654B/no
Publication of NO164654C publication Critical patent/NO164654C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO850564A 1984-02-15 1985-02-14 Analogifremgangsmaate for fremstilling av terapeutisk aktive (2-okso-1,2,3,5-tetrahydroimidazo (2,1-b)kinazolinyl)-oksylakylamider. NO164654C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58040984A 1984-02-15 1984-02-15

Publications (3)

Publication Number Publication Date
NO850564L NO850564L (no) 1985-08-16
NO164654B NO164654B (no) 1990-07-23
NO164654C true NO164654C (no) 1990-10-31

Family

ID=24320992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO850564A NO164654C (no) 1984-02-15 1985-02-14 Analogifremgangsmaate for fremstilling av terapeutisk aktive (2-okso-1,2,3,5-tetrahydroimidazo (2,1-b)kinazolinyl)-oksylakylamider.

Country Status (13)

Country Link
US (1) US4690925A (de)
EP (1) EP0153152A3 (de)
JP (1) JPS60193991A (de)
AU (1) AU581205B2 (de)
CA (1) CA1254557A (de)
DK (1) DK69285A (de)
ES (2) ES8607299A1 (de)
FI (1) FI81578C (de)
HU (2) HU193409B (de)
IL (1) IL74349A (de)
NO (1) NO164654C (de)
NZ (1) NZ211117A (de)
ZA (1) ZA851131B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
IL74349A (en) * 1984-02-15 1988-07-31 Syntex Inc (2-oxo-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolinyl)-oxyalkylamides,their preparation and pharmaceutical compositions containing them
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
JPH06508842A (ja) 1991-07-05 1994-10-06 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 置換ピリダジンの皮膚病に対する使用
CA2113115A1 (en) * 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31617A (en) * 1861-03-05 photo-uthcqfupheh
USRE31617E (en) 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4070470A (en) * 1974-06-24 1978-01-24 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting carbostyrils, their compositions and method of use
US4313947A (en) * 1974-06-24 1982-02-02 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting 2-oxyindoles, their compositions and method of use
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
NZ187452A (en) * 1977-06-10 1980-05-27 Otsuka Pharma Co Ltd N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
JPS54163825A (en) * 1978-06-15 1979-12-26 Otsuka Pharma Co Ltd Phosphoesterase inhibitor
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
US4551459A (en) * 1983-02-16 1985-11-05 Syntex (U.S.A.) Inc. Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxyalkylamides
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
JPS604186A (ja) * 1983-06-21 1985-01-10 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン化合物
IL74349A (en) * 1984-02-15 1988-07-31 Syntex Inc (2-oxo-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolinyl)-oxyalkylamides,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0153152A2 (de) 1985-08-28
ES549920A0 (es) 1986-04-16
FI81578B (fi) 1990-07-31
IL74349A0 (en) 1985-05-31
EP0153152A3 (de) 1987-07-15
FI850618L (fi) 1985-08-16
AU581205B2 (en) 1989-02-16
AU3875485A (en) 1985-08-22
DK69285A (da) 1985-08-16
CA1254557A (en) 1989-05-23
NO164654B (no) 1990-07-23
NZ211117A (en) 1987-10-30
JPS60193991A (ja) 1985-10-02
ES540403A0 (es) 1986-06-01
HUT36122A (en) 1985-08-28
ZA851131B (en) 1986-09-24
DK69285D0 (da) 1985-02-14
ES8606297A1 (es) 1986-04-16
US4690925A (en) 1987-09-01
IL74349A (en) 1988-07-31
HU193409B (en) 1987-10-28
ES8607299A1 (es) 1986-06-01
FI81578C (fi) 1990-11-12
NO850564L (no) 1985-08-16
HU191316B (en) 1987-02-27
FI850618A0 (fi) 1985-02-14

Similar Documents

Publication Publication Date Title
NO166639C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte, basiske 2-aminotetraliner.
NO162238C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater.
NO871267L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazepinforbindelser.
NO163691C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-acryl-piperazinalkanamider.
NO167142C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
NO162514C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinonderivater.
NO160521C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 13alfa- alkylgonaner.
NO871879D0 (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktive heterocykliske forbindelser.
NO874869L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO164097C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-(n-substituert-guanidino)-4-hetero-aryl-tiazol-derivater.
NO864879D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiasolforbindelser.
NO166080C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,8-trifluorkinoliner.
NO164168C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,7,4-triazolforbindelser.
NO164654C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (2-okso-1,2,3,5-tetrahydroimidazo (2,1-b)kinazolinyl)-oksylakylamider.
NO165400C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cefemforbindelser.
NO165842C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
NO167570C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive flavonforbindelser.
NO164897C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxazolidinonderivater.
NO165069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklopentyletere.
NO161177C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive tioetere.
NO161313C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorallylaminderivater.
NO163330C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive isokinolinderivater.
NO164417C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive iminothiazolidinderivater.
NO162072C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tienopyridinderivater.
NO163896C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive spiro-(1,8)-nafthyridin-dioner.